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TGF-b is a negative regulator of liver growth. Smad
family of genes, as mediators of TGF-b pathway, are
candidate tumor suppressor genes in hepatocellular
carcinoma (HCC). We studied 35 HCC and non-tumour
liver tissues for possible mutations in Smad2 and Smad4
genes. Three tumours displayed somatic mutations; two
in Smad4 (Asp332Gly and Cys401Arg) and one in
Smad2 (Gln407Arg) genes. All three mutations were A:T
? G:C transitions suspected to result from oxidative
stress as observed in mitochondrial DNA. These
observation demonstrate that TGF-b pathway is altered
in hepatocellular carcinoma.
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Introduction
Hepatocellular carcinoma (HCC), one of the ten most
frequent cancers world-wide, is associated with well
defined viral and non-viral etiological factors. Chronic
infection with hepatitis B (HBV) and hepatitis C
(HCV) viruses, and oral intake of aflatoxins are the
major causes of HCC, but the molecular mechanisms
underlying the malignant transformation of hepato-
cytes are largely unknown (Ozturk, 1995). Long latent
period (20 – 30 years) between viral infections and the
development of HCC suggests the multi-step nature of
hepatocarcinogenesis (Ozturk, 1995). Genetic studies
provide sucient evidence for this hypothesis. Allelo-
type studies indicate that many chromosomal regions
(i.e. 1p, 1q, 4q, 5q, 6q, 8p, 8q, 9p, 10q, 11p, 13q, 14q,
16p, 16q, 17p) undergo structural changes in HCC
(Nagai et al., 1997; Piao et al., 1998; for review see
Grisham, 1996). Some of these chromosomal changes
are associated with dierent tumour stages, suggesting
that they are associated with the tumour progression
(Tsuda et al., 1990). The critical genes located at these
chromosomal regions are mostly unknown. To date
only a few genes including p53, p16, mannose-6-
phosphate/insulin-like growth factor II receptor
(M6P/IGFIIR), b-catenin (Miyoshi et al., 1998; De la
Coste et al., 1998) and cyclin D have been shown to be
significantly altered in HCC (for review see Grisham,
1996). Both the suspected genetic heterogeneity of
HCC and the discordance between allelotype and
mutation studies strongly suggest that many other
genes undergo somatic mutations in these tumours.
Genes encoding for proteins involved in the control
of hepatocyte growth (i.e. inhibitors of hepatocyte
proliferation and the activators of apoptotic cell death)
are potential tumour suppressor genes for HCC.
Transforming growth factor-b (TGF-b) and activin
are potent inhibitors of hepatocyte growth (Fausto et
al., 1995). TGF-b is also known to induce apoptosis in
both hepatocytes and HCC cell lines (Oberhammer et
al., 1992; Gressner et al., 1997). Certain transformed
cells, however, show defective response to TGF-b-
induced growth inhibition including some liver-derived
cell lines (Fynan and Reiss, 1993). Based on these
observations, genes involved in TGFb signalling
pathway are candidate tumour suppressor genes in
HCC. For instance, M6P/IGFIIR gene was shown to
be mutated in about 25% of HCCs displaying LOH at
the M6P/IGFIIR locus (De Souza et al., 1995).
Although the protein product of this gene has a
broad range of cellular functions, it is suspected to be
an activator of latent TGF-b in the liver. In addition,
at least two other genes involved in HCC, namely
cyclin D and c-myc genes appear to be among the
ultimate targets of TGFb signalling pathway, as their
expression level is modified following treatment of
dierent cell lines with TGFb (Alexandrow and Moses,
1995, Grisham, 1996).
Recently, the Smad family of proteins have been
discovered as mediators of TGFb signalling pathway.
Eight distinct members of Smad family have been
identified in vertebrates and at least two of them,
namely Smad2 and Smad4 act as tumour suppressor
genes in humans (Heldin et al., 1997; Baker and
Harland, 1997). Smad4 and Smad2 are both involved
in cytoplasmic signal transduction upon activation of
TGF-b and activin receptors by their specific ligands
(for review see Heldin et al., 1997). Missense mutations
within carboxyl terminal eector domains of Smad2
and Smad4 have been identified in dierent cancers
including the cancers of pancreas (Hahn et al., 1996;
Moskaluk et al., 1997), biliary tract (Hahn et al., 1998),
colon (Eppert et al., 1996; Riggins et al., 1996; Takagi
et al., 1996), lung (Uchida et al., 1996), as well as head
and neck carcinomas (Kim et al., 1996). Smad2 and
Smad4 appear to be the most critical targets of
mutational inactivation because a study based on 167
tumour samples suggested that mutational inactivation
of the other Smad genes does not account for the
widespread resistance of cancer cells to TGF-b
(Riggins et al., 1997). Based on these indications, we
selected Smad2 and Smad4 (also called JV18-1 and
DPC4 respectively) as candidate tumour suppressor
genes in HCC and studied 35 primary tumours as well
as six hepatoma cell lines for possible mutations. We
demonstrate that both genes display somatic mutations
in HCC, but the mutation frequency is low. We will
discuss possible implications of these observations in
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relation with the role of TGFb signalling pathway in
hepatocellular carcinogenesis.
Results and Discussion
To investigate the potential involvement of the Smad2
and Smad4 genes in HCCs, we screened 35 HCC
samples as well as six hepatoma cell lines for possible
genetic alterations of these genes. Initially, six
hepatoma cell lines were tested by RT–PCR for the
expression of Smad2 and Smad4 genes. All cell lines
expressed both Smad2 and Smad4 genes and RT –PCR
products did not show size alteration in the respective
coding region (data not shown). Homozygous and
large deletions of Smad2 and Smad4 genes have been
reported for other cancers (Hahn et al., 1996, Riggins
et al., 1996). But the hepatoma cell lines tested here did
not show such alterations.
Next, we studied genomic DNA from 35 primary
tumours. The majority of the previously identified
Smad2 and Smad4 gene mutations are located within
the region coding for the highly conserved carboxyl
terminal domains, corresponding to exon 8 – 11 of both
genes (Hahn et al., 1996; Riggins et al., 1996; Schutte
et al., 1996, Hahn et al., 1998). In addition, two
mutations, one located in exon 4 of Smad2 and
another located in exon 2 of Smad4 aecting the N-
terminal regions of Smad2 and Smad4 (Arg133Cys and
Arg100Thr, respectively) proteins have been described
in colon and pancreas cancers (Hata et al., 1997; Shi et
al., 1997). To test whether HCCs display similar
mutations, we studied exon 4 of Smad2, exon 2 of
Smad4, in addition to exons 8 – 11 of both genes by
SSCP analysis. A total of seven HCC samples showed
altered migration pattern (see Figure 1 for exon 8
alterations as an example). Four of these alterations
(three in exon 8 and one in exon 10 of Smad4 gene)
were also present in the non-tumour liver samples of
the respective patients. DNA sequence analysis of these
four tumours did not reveal any alteration in exonic
sequences and immediately flanking intronic regions
(data not shown) suggesting that constitutional
polymorphisms aecting intronic sequences were
present in these patients. The other three SSCP
alterations were seen only in tumour DNA, but not
in non tumorous liver DNA. Sequence analysis of
tumour and non-tumour liver DNA samples from
Figure 1 SSCP analysis of Smad4 gene (exon 8) in hepatocellular
carcinomas. T and N denotes tumour and matching non-tumour
liver DNA, respectively. T19, T29 and T37, as well as their
matching non-tumour liver DNAs (N18, N28 and N36,
respectively) display abnormally migrating bands
Figure 2 SSCP and DNA sequence analyses of Smad2 (exon 10) and Smad4 (exons 8 and 9) genes indicate the presence of somatic
mutations in three hepatocellular carcinomas. (a) SSCP analysis of tumours demonstrating mutant allelic shifts in tumours T49, T37
and T39 (the asterisk indicates the samples displaying band-shifts); (b) Sequence analysis of hepatocellular carcinoma (T) and non
tumour liver tissue (N) DNAs of the samples identified in a. Somatic single base-pair mutations (A:T ? G:C transitions) were
underlined
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three patients revealed three dierent somatic muta-
tions (Figure 2). Two tumour DNAs (T37 and T39)
displayed missense mutations in Smad4 gene. An A?
G transition at codon 332, leading to a Asp332Gly
change was observed in T39. The other Smad4
mutation was a T?C transition at codon 401 leading
to a Cys401Arg replacement in T37. One tumour DNA
(T49) carried a transition mutation (A?G) at codon
407 of Smad2 gene leading to a Gln407Arg change
(Figure 2).
All three of these somatic mutations were novel and
have not been described previously. They all appear to
be deleterious mutations because of the strong side
chain charge changes in the replaced amino acid
residues resulting from each mutation. Crystal struc-
ture of C-terminal domain of Smad4 reveals that Asp
332 residue is located in the trimeric interface region
and forms a hydrogen bond with His 371 (Shi et al.,
1997). Because this interface region is crucial for
trimeric complex formation, it is likely that
Asp332Gly change, breaking the hydrogen bond,
blocks the TGFb signal by preventing trimer forma-
tion of Smad4 protein. The Cys401 residue of Smad4 is
highly conserved between Smad family members. This
residue is located within the b6 sheet which makes the
hydrophobic core, the b sandwich of Smad4 protein.
Amino acid change from cysteine to arginine will most
probably aect Smad4 protein function by changing
the conformation of the b sandwich. Gln407 of Smad2
is located in a region that is homologous to H4 helix
domain of Smad4, also in trimeric interface region (Shi
et al., 1997).
All three mutations are located in the MH2 domain
of Smad proteins. These proteins consist of three
structurally and functionally distinct domains. The
amino and carboxyl terminal regions of Smad proteins
are referred to as MH1 and MH2 domains, respec-
tively. The central region serves as a linker domain
between MH1 and MH2 domains. The MH2 domain
of Smad 1, 2 and 3 mediates homomeric interactions
and is responsible for heteromeric interactions with
Smad4. The MH2 domain also called eector domain
is able to mimic the activity of the full length proteins
(Heldin et al., 1997). Thus it is very likely that the three
mutations described here are not random mutations
and that they either aect protein-protein interactions
or destabilise the whole structure of the protein. Taken
together, all three mutations described here appear to
be deleterious mutations which may aect TGFb
signalling pathway in these tumours.
The tumours described here have been previously
examined for the presence of p53 gene mutations and
HBV DNA (Unsal et al., 1994). As shown in Table 1,
HBV DNA was present in all three tumours with Smad
mutations. p53 was mutant (Arg249Ser) in T37 but not
in two other tumours. Thus, it appears that Smad
mutations described here are associated with HBV
infection and that there appears to be no correlation
with p53 mutations. On the other hand, it is
noteworthy that all three mutations described here
aected A:T pairs with a consistent change to G:C
pairs. This pattern was recently shown to be a common
type of mitochondrial DNA mutation in colorectal
tumours and explained by high level of reactive oxygen
species (ROS) in mitochondria (Polyak et al., 1998).
Similarly, Smad gene mutations observed here may be
caused by high levels of ROS in the precursor cells of
these tumours.
Previous studies showed that Smad4 is altered in a
significant portion of pancreatic (Hahn et al., 1996)
and common bile duct cancers (Hanh et al., 1998) and
a minority of colorectal cancers (Eppert et al., 1996;
Takagi et al., 1996) but rarely in other tumours
(Schutte et al., 1996). Smad2 gene alterations are also
limited to a small fraction of colorectal and lung
cancers (Riggins et al., 1996, 1997; Uchida et al., 1996.
Our data suggest that, Smad2 and Smad4 gene
mutations may contribute to a fraction of HCCs.
Low prevalence of these alterations may be explained
with genetic heterogeneity of HCC (Unsal et al., 1994).
Indeed, Kawate et al. (1999) reported very recently that
mutations of TGFb-receptor II, Smad2 and Smad4
mutations are rare in HCCs from Japan. In addition,
Smad mutations in HCC could occur at late stages
during tumor progression. In an animal model of
compound heterozygosity for APC and Smad4,
inactivation of Smad4 gene resulted in the malignant
progression of the intestinal and colonic polyps
initiated by LOH in the APC gene. This observation
suggested the inactivation of Smad4 as a late event in
carcinogenesis (Takaku et al., 1998).
In conclusion, we identified Smad gene mutations in
HCC at a frequency of *10%. The occurrence of these
mutations provides evidence that TGFb pathway is
altered in HCC. In conformation to our hypothesis,
TGFb itself was identified as a new form of tumour
suppressor for liver and lung cancers in mice
heterozygous for deletion of the TGFb gene (Tang et
al., 1998). However, the low frequency of Smad gene
mutations in human HCC also suggest that other genes
of TGFb pathway may also be alterated in these
tumours.
Materials and methods
Tumour samples and cell lines
We analysed a total of 35 pair of DNA samples isolated from
HCC and non-tumour liver tissues from patients living in
dierent geographical regions including Mozambique (n=7),
South Africa (n=11), China (n=8), Japan (n=6) and
Germany (n=3). Characteristics of these tumours and
methods for DNA isolation have been described previously
(Unsal et al., 1994). We also analysed six established
Table 1 Smad gene mutations in hepatocellular carcinoma
Predicted p53 HBV
Tumour Age Country Gene Exon Mutation eect Status DNA Stage
T49
T37
T39
14
36
34
South Africa
Mozambique
Swaziland
Smad2
Smad4
Smad4
10
9
8
CAG to CGG
TGC to CGC
GAT to GGT
Gln-407-Arg
Cys-401-Arg
Asp-332-Gly
WT
Arg-249-Ser
WT
+
+
+
Late
Late
Late
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hepatoma cell lines (HepG2, Huh7, Mahlavu, PLC/PRF/5,
Hep3B and Focus). Genomic DNA from cell lines was
isolated as described (Unsal et al., 1994). Total RNA from
cell lines were isolated using Ultraspect RNA extraction kit
(Biotecx) according to the manufacturer’s directions.
RT–PCR
cDNAs were synthesised by MMLV reverse transcriptase
(SuperScriptTM, Gibco) using oligo (dT)12 – 18 primers. The
entire coding region of Smad2 and Smad4 genes were
amplified using primers indicated in Table 2. PCR was
performed in 50 ml reaction mixture containing 1 ml of the
complementary DNA mix, 16Taq buer (MBI), 1.5 mM
MgCl2, 1 unit of Taq DNA polymerase, 20 pmol of each
primer and 10 mM each of dNTPs. PCR conditions consisted
of 35 cycles of denaturation at 948C for 60 s, annealing at
temperatures varying between 55 – 568C (see Table 2 for
primer sequences and annealing temperatures) for 30 s,
followed by an extension at 728C for 90 s. The final cycle
included an additional 3 min extension at 728C.
SSCP analysis
PCR was performed using 50 ng genomic DNA, 16Taq
buer (MBI), 1.5 mM MgCl2, 1 unit of Taq DNA
polymerase, 20 pmol of each primer, 40 mM each of dNTPs,
2 mCi [a-32P]dATP (1000 Ci/mmol, Amersham) in a final
volume of 25 ml. PCR conditions consisted of 30 cycles of
denaturation at 948C for 45 s, annealing at temperatures
varying between 50 – 608C (see Table 2 for primer sequences
and annealing temperatures) for 30 s, followed by an
extension at 728C for 1 min. The final cycle included an
additional 3 min extension at 728C. SSCP analysis of PCR
products was done at both 48C and room temperature, on
10% of acrylamide gel with or without glycerol as well as on
MDE gels (FMC Bioproducts). Gels were mounted on a 3M
Whatman paper, dried and visualised by autoradiography.
Sequence analysis
For the analysis of tumour PCR products, aberrantly
migrating radioactive bands were recovered from SSCP gels
in order to enrich for mutant DNA fragments before
sequencing. Selected bands were cut with a razor blade,
eluted into TE and reamplified as described, except that
[a-32P]dATP was omitted. Non-tumour PCR products were
analysed directly following non-radioactive PCR amplifica-
tion. PCR products were purified using Quick PCR
purification kit (Qiagen). For sequencing reactions, dye
terminator cycle sequencing ready reaction kit (ABI Prism)
was used. Reaction products were then analysed using the
ABI Prism 377 fluorescent DNA sequencer (Perkin Elmer).
Identified mutations were confirmed by DNA sequencing of
Table 2 List of primers and annealing temperatures
Primer name Primer sequence Product size (bp) TA (8C) Ref.
Smad4 Ex2 F
Smad4 Ex2 R
TTCTAGGTGGCTGGTCGGAA
CAGGTGATACAACTCGTTCG
175 56 This study
Smad4 Ex8 F
Smad4 Ex8 R
TTTCTCATGGGAGGATGTTC
CAATTTTTTAAAGTAACTATCTGAC
264 56 Hahn et al., 1998
Smad4 Ex9a F
Smad4 Ex9a R
TATTAAGCATGCTATACAATCTG
CTGTCTAAGTAGTAACTCTTG
194 57 Hahn et al., 1998
Smad4 Ex9b F
Smad4 Ex9b R
CAAAGGTGTGCAGTTGGAATG
CTTCCACCCAGATTTCAATTC
234 57 Hahn et al., 1998
Smad4 Ex10 F
Smad4 Ex10 R
GAATTTTCTTTATGAACTCATAG
TTTAAAAAAGAATGAAAAGCATAC
213 57 Hahn et al., 1998
Smad4 Ex11 F
Smad4 Ex11 R
CTGATGTCTTCCAAACTCTTTTCTG
TGTATTTTGTAGTCCACCATC
299 57 Hahn et al., 1998
Smad2 Ex4 F
Smad2 Ex4 R
TCTGATAGTGGTAAGGGTTT
GTCTCTTGATGGTCGTCTC
189 56 This study
Smad2 Ex8 F
Smad2 Ex8 R
CAGTTACTTACTCAGAACCT
GCCTACATTCTGAGTATACAG
269 53 This study
Smad2 Ex9 F
Smad2 Ex9 R
CCAAAGTCACACTGAAATAG
AGCAAGTTGACATGATAGG
242 57 This study
Smad2 Ex10 F
Smad2 Ex10 R
GCATGCTCATATTCTAAAAC
ACTGTGGAAATTTAAGAACC
275 50 This study
Smad2 Ex11 F
Smad2 Ex11 R
GCCTGTGGACTTGAATTTCAT
GGACTTGATTGGTGAAGCTTT
192 56 This study
Smad2 ECR F
Smad2 ECR R
GGATCCTAATACGACTCACTATAGGGAGACCAC-
CATGGGTAAGAACATGTCGTCCAT
TTTCCATGGGACTTGATTGG
1477 56 Riggins et al.,
1996
Smad4 ECR F
Smad4 ECR R
AAGCGGATCCGCTTCAGAAATTGGAGA
AAGCAAGCTTCCATCCTGATAAGGTTAAGGG
1769 55 This study
Ex and ECR identify primers used for PCR amplifications of exons and the entire coding regions, respectively
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independent PCR products after cloning into pGEM-T
plasmid (Promega).
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